Attia Steps Down from David Protein; Biograph 'Won't Comment' on His Involvement - DPP, BIOP

[The Lead] Dr. Peter Attia, Chief Science Officer at David Protein (DPP), steps down amid fallout from Epstein-related documents. Attia, a prominent longevity expert, has been instrumental in the company's growth post-Series A funding in May 2025. His departure follows a public apology for past emails involving Epstein, which David Protein announced on February 4, 2026. [Supporting Details] Attia, known for his book "Outlive" and podcast, was also an early investor in David Protein, which has seen significant expansion since launching its flagship protein bar in September 2024. The company raised $75 million in its Series A round. Biograph, Attia's healthcare startup (BIOP), has distanced itself, refusing to comment on his involvement. The startup, backed by investors like Vy Capital and Human Capital, offers premium health services for a premium price, now omitting Attia's name from its website.